Trials (Sep 2021)
Correction to: Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries
- Moses Badio,
- Edouard Lhomme,
- Mark Kieh,
- Abdoul Habib Beavogui,
- Stephen B. Kennedy,
- Seydou Doumbia,
- Bailah Leigh,
- Samba O. Sow,
- Alpha Diallo,
- Daniela Fusco,
- Matthew Kirchoff,
- Monique Termote,
- Renaud Vatrinet,
- Deborah Wentworth,
- Helène Esperou,
- H. Clifford Lane,
- Jerome Pierson,
- Deborah Watson-Jones,
- Céline Roy,
- Eric D’Ortenzio,
- Brian Greenwood,
- Genevieve Chêne,
- Laura Richer,
- James D. Neaton,
- Yazdan Yazdanpanah,
- the PREVAC study team
Affiliations
- Moses Badio
- Partnership for Research on Ebola Virus in Liberia (PREVAIL)
- Edouard Lhomme
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform
- Mark Kieh
- Partnership for Research on Ebola Virus in Liberia (PREVAIL)
- Abdoul Habib Beavogui
- Centre National de Formation et de Recherche en Santé Rurale de Mafèrinyah
- Stephen B. Kennedy
- Partnership for Research on Ebola Virus in Liberia (PREVAIL)
- Seydou Doumbia
- University of Sciences, Technique and Technology of Bamako
- Bailah Leigh
- College of Medicine and Allied Health Sciences (COMAHS), University of Sierra Leone
- Samba O. Sow
- Centre pour le Développement des Vaccins
- Alpha Diallo
- INSERM, Pôle de Recherche Clinique
- Daniela Fusco
- INSERM, Pôle de Recherche Clinique
- Matthew Kirchoff
- National Institute of Allergy and Infectious Diseases
- Monique Termote
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform
- Renaud Vatrinet
- REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm
- Deborah Wentworth
- Division of Biostatistics, School of Public Health, University of Minnesota
- Helène Esperou
- INSERM, Pôle de Recherche Clinique
- H. Clifford Lane
- National Institute of Allergy and Infectious Diseases
- Jerome Pierson
- National Institute of Allergy and Infectious Diseases
- Deborah Watson-Jones
- London School of Hygiene & Tropical Medicine
- Céline Roy
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform
- Eric D’Ortenzio
- REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm
- Brian Greenwood
- London School of Hygiene & Tropical Medicine
- Genevieve Chêne
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform
- Laura Richer
- Univ. Bordeaux, Inserm, Bordeaux Population Health Research, Center, UMR 1219, CHU Bordeaux, CIC 1401, EUCLID/F-CRIN Clinical Trials Platform
- James D. Neaton
- Division of Biostatistics, School of Public Health, University of Minnesota
- Yazdan Yazdanpanah
- REACTing, Institut Thématique Immunologie, Inflammation, Infectiologie et Microbiologie, Inserm
- the PREVAC study team
- DOI
- https://doi.org/10.1186/s13063-021-05572-3
- Journal volume & issue
-
Vol. 22,
no. 1
pp. 1 – 1
Abstract
No abstracts available.